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In a recently published paper[@CIT0001] fosfomycin is claimed to be an effective antibiotic on Gram-negative bacteria (GNBs) causing urinary tract infections (UTIs) in Pondicherry in Southern India. Monotherapy of fosfomycin is not recommended due to chances for development of resistance during therapy is a serious concern[@CIT0002] therefore the authors suggested using fosfomycin with amoxyclav and nitrofurantoin.[@CIT0001] Researchers reported fosfomycin as the most effective antibiotic inhibiting 100% *E. coli*, 70% *Klebsiella* sp., and 50% *Pseudomonas* sp. and 40% *Enterobacter* sp. isolates from UTIs. Fosfomycin was also effective against extended-spectrum β-lactamases (ESBL), carbapenemase and AmpC[@CIT0001] producers. A recent report from Bareilly[@CIT0003], Northern India indicated *E. coli* as the most common bacteria associated with UTI infections both in humans and animals similar to the report from Pondicherry.[@CIT0001] However, the report from Northern India reported only that only 12.9% and 33.3% isolates of GNBs associated with UTIs in humans and animals were susceptible to fosfomycin. The study[@CIT0003] reported that only 8.3% and 25% of *E. coli* isolates from UTI cases were susceptible to fosfomycin. The two studies[@CIT0001],[@CIT0003] concurred ([Table 1](#T0001){ref-type="table"}) each other concerning the efficacy of meropenem and nitrofurantoin but contradicted each other for the susceptibility of *E. coli* isolates ([Table 1](#T0001){ref-type="table"}) and other GNBs from UTIs to other antibiotics. Table 1Susceptibility patterns of *Escherichia coli* associated with urinary tract infectionsAntimicrobials testedPercent sensitive isolates under study in Pondicherry[@CIT0001]Percent sensitive isolates under study in Bareilly[@CIT0003]*E. coli*, human cases (n=217)*E. coli*, human cases (n=50)*E. coli*, animal cases (n=37)Fosfomycin1008.325.0Nitrofurantoin86.689.478.4Ciprofloxacin0.014.629.7Gentamicin4.660.045.9Meropenem84.380.687.1Ceftriaxone0.531.750.0Ceftazidime6.940.746.7

Looking at both of the studies,[@CIT0001],[@CIT0003] we understand a wide variation in susceptibility ([Table 1](#T0001){ref-type="table"}) of the bacteria from different regions and different patients causing similar infections. Thus, a generalization of observation should be avoided for suggesting or using antimicrobial chemotherapy, and more elaborate and continues surveys and monitoring the antimicrobial drug-resistance of important pathogens should be established and regularly published for proper guidance of the clinicians.
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